Recall Insurance Coverage Gaps for Medical Device Companies

Recall coverage is the line where the gap between what manufacturers think they have and what they actually have is largest. A program with a respectable overall recall limit can still leave the manufacturer materially uninsured if the sub-limits, triggers, and coordination with other lines are not engineered against the actual exposure. The structural problem: recall is a complex line with multiple cost categories, and the standard policy is built to respond to a basic recall scenario rather than to the operationally complex events that real recalls become.

This article walks through the specific gaps that show up most consistently in medical device recall programs, why each gap forms, and the wording and structural changes that close them. It is a companion to the broader recall coverage piece and assumes basic familiarity with what recall coverage is. The focus here is structural diagnosis.

Gap One: Business Interruption Sub-Limit Inadequacy

Business interruption is the largest cost component in most actual recalls. The affected SKU is off the market while the recall is executed and remediated. For a single-product company or a company with a concentrated revenue mix, the BI exposure can exceed every other recall component combined.

The gap forms when the recall policy is purchased on the headline overall limit without attention to the BI sub-limit inside it. A policy with a substantial overall limit but a BI sub-limit at a small fraction of overall leaves the manufacturer underinsured for the component that typically drives the loss.

Why it forms. The headline limit is the easiest number to discuss in placement. Sub-limits live in the policy schedule and require active engagement to review. Manufacturers focused on getting the placement done at acceptable premium often accept the standard sub-limit structure without specific evaluation against their revenue concentration.

How to close it. Treat BI sub-limit as the primary placement variable rather than the overall recall limit. The BI sub-limit should be sized to the manufacturer’s projected revenue from the affected SKU over the realistic off-market period, not to a standard percentage of the overall limit. For single-product companies, the BI sub-limit may need to equal or approach the overall limit; the standard form typically does not produce this without specific negotiation.

Gap Two: Missing or Thin Third-Party Recall Coverage

Third-party recall responds when a component supplier or contract manufacturer’s quality event triggers the named insured’s recall. The recall happens at the named insured (the manufacturer named on the 510(k) or PMA), but the operational root cause is upstream. Third-party recall provides the coverage mechanism for this scenario.

The gap forms in two ways. First, the policy may not include third-party recall trigger language at all; the standard first-party recall coverage assumes the manufacturer’s own quality system produced the issue. Second, where third-party recall is included, the sub-limit may be a small fraction of the overall recall limit, leaving the manufacturer materially under-protected for supplier-driven recalls.

Why it forms. Manufacturers with material supplier dependencies often think about contractual indemnification as the answer to supplier-driven exposure. Indemnification is a contract law mechanism that works when the supplier is solvent and the contract is well-drafted. Third-party recall is the insurance mechanism that works when those preconditions are not met or when the indemnification process is slower than the recall response timeline requires.

How to close it. Verify that third-party recall is explicit in the form, not implicit. Negotiate a sub-limit that reflects the manufacturer’s actual supplier risk profile. For manufacturers with single-source CMO relationships or sole-source critical components, third-party recall coverage should approach the first-party limit rather than sitting at a thin sub-limit.

Gap Three: Market Withdrawal Outside Recall Triggers

Not every field action is a Class I, II, or III recall. Market withdrawals for labeling deficiencies, packaging issues, stability concerns identified post-launch, or other non-safety quality matters carry many of the same operational costs as a recall but may sit outside the policy’s recall trigger.

The gap forms when the policy defines the covered event narrowly (a Class I or II recall under 21 CFR Part 7) and the manufacturer’s field action does not meet that definition. The operational costs (unit retrieval, customer communication, business interruption) are real; the coverage is not responsive because the trigger was not met.

Why it forms. Standard recall policy wording typically anchors the trigger on FDA recall classification or the manufacturer’s recall declaration. Market withdrawals fall outside the classification framework even when they involve the same operational mechanics.

How to close it. Negotiate explicit market withdrawal coverage or broaden the trigger language to address “corrections and removals” under 21 CFR Part 806 rather than only formally classified recalls. The wording change is not always available without premium adjustment, but the coverage scope expansion is meaningful.

Gap Four: Software-Driven Recall Response Under Legacy Forms

For SaMD, connected devices, and other software-bearing devices, a field action may involve software patch deployment, version management across the installed base, and verification of update receipt rather than physical unit retrieval. The operational mechanics differ from a traditional unit-retrieval recall.

The gap forms when the policy form was written before software-driven recall response became common. Standard wording may assume physical unit return, may not contemplate patch deployment costs, may exclude software-only “corrections” from the recall definition, or may not respond to Section 524B-driven vulnerability disclosure events.

Why it forms. Legacy medical device recall forms predate the maturation of SaMD and connected devices. Policy forms have been updated for newer placements, but many existing programs are still operating on legacy wording.

How to close it. Review the policy form against the manufacturer’s actual device portfolio. Where software-bearing or connected devices are in the portfolio, confirm the policy wording responds to patch deployment, version verification, post-market vulnerability disclosure, and the operational costs specific to software-driven field actions. Modern forms address these directly; legacy forms often do not without amendment.

Gap Five: International Vigilance Coverage Gaps

For devices that are CE-marked or sold internationally, EU MDR Articles 87 to 91 impose vigilance and Field Safety Corrective Action obligations that operate in parallel to the US recall framework. The reporting timelines run to 2 days for serious public health threats, 10 days for death or unanticipated serious deterioration, and 15 days for serious incidents. The MIR form 7.3.1 became mandatory in May 2026.

The gap forms when the policy’s territory and jurisdiction language does not extend to international vigilance events, or when the policy responds to US recalls only and treats the EU vigilance obligation as a separate matter. The manufacturer is then responding to two regulatory regimes with one policy that responds to only one.

Why it forms. Standard US recall policy wording assumes US distribution. International extensions exist but are not always included by default, particularly for manufacturers whose international distribution is a smaller portion of their footprint.

How to close it. Confirm explicit international extension covering EU MDR vigilance and FSCA events for any CE-marked product. The extension should cover the operational costs of international corrective actions, including the documentation overhead that the MIR form structure imposes. Where the manufacturer also operates in other regulated international markets (Canada, Japan, Australia), confirm coverage extends to those frameworks as well.

Gap Six: Notification Cost Sub-Limit Under Early Alert

The Early Alert Program expansion in September 2025 changed the public timeline for recalls. Posting now occurs within days to weeks of the initial customer notification letter, compared with the 2-3 month delay under the prior framework. The notification cost component of a recall now operates under much shorter operational pressure and a larger affected audience window.

The gap forms when the policy’s notification cost sub-limit was sized to the pre-2025 timeline. Manufacturers issuing customer letters now operate under a shorter window before public visibility, which can require larger and faster notification activities (HCP letters, hospital coordination, patient communication where applicable, call center capacity).

Why it forms. Sub-limits sized in prior placement cycles may not have been revisited against the new operational reality.

How to close it. Review the notification cost sub-limit against the manufacturer’s actual notification volume capacity. For manufacturers with large hospital or HCP customer bases, the sub-limit should reflect the cost of a high-volume, rapid notification event. The Early Alert timeline does not change what the policy covers; it changes the volume and pace at which the costs are incurred.

Gap Seven: Brand Rehabilitation Sub-Limit Inadequacy

Brand rehabilitation costs (post-recall marketing, sales force re-engagement, customer retention activities, regulatory communication to rebuild customer confidence) often run materially longer than the recall itself. For a manufacturer with concentrated customer relationships or a premium-positioned product, brand rehabilitation can be the second-largest recall cost after business interruption.

The gap forms when the brand rehabilitation sub-limit is sized as a small percentage of the overall limit. Standard forms often include a brand rehabilitation grant that is thin relative to actual exposure.

Why it forms. Brand rehabilitation is the recall component that requires the most subjective assessment of need. It does not produce a clear unit-by-unit cost like notification or retrieval. Sub-limits get sized conservatively by carriers and accepted as standard by buyers.

How to close it. Negotiate a larger brand rehabilitation sub-limit or align it more closely with the BI sub-limit. The two components address related but distinct costs (BI is the lost revenue during the off-market period; brand rehabilitation is the cost of rebuilding the customer relationship afterward). Both should be sized to the actual exposure.

Gap Eight: Aggregation Between Recall and Products Policies

A field action commonly produces both a recall response (first-party retrieval, notification, business interruption) and a products liability response (third-party bodily injury or property damage claims arising from units used before retrieval). The two policies have different triggers and respond to different costs, but they typically share an underwriter’s risk perception of the manufacturer.

The gap forms in two ways. First, the policies may aggregate at the carrier level: a single insurance group writing both recall and products may apply a combined limit cap that limits how the two policies respond together. Second, the policies may produce coverage overlap or coverage debate at claim, particularly for events that produce both first-party and third-party costs.

Why it forms. Carriers writing both lines often have internal aggregation rules that are not visible at placement. Coordination between the two policies is sometimes left to claim handling rather than negotiated at placement.

How to close it. Confirm the carrier-level aggregation arrangement at placement. Where aggregation exists, evaluate whether splitting the lines between separate carriers improves the overall risk transfer. Negotiate clear coordination language between the two policies for events that produce both types of cost.

Gap Nine: Recall Response for Combination Products

Combination products (drug-device, biologic-device, software-drug) are regulated under multiple FDA centers with different recall and vigilance frameworks. A recall affecting a combination product may invoke device recall, drug recall, and biologic recall obligations simultaneously, each with its own classification framework and reporting timeline.

The gap forms when the policy was written for the device component only and does not respond to the drug or biologic portion of the combination product recall.

Why it forms. Combination products are a smaller portion of the device market and are often placed with device-focused recall coverage without specific attention to the multi-center regulatory dimension.

How to close it. For combination product manufacturers, confirm the recall policy responds to all of the FDA centers with jurisdiction over the product. Where the policy is device-focused, evaluate whether additional coverage or amended wording is needed to address the drug or biologic dimension.

Gap Ten: Recall During M&A

A manufacturer mid-transaction at the time a recall arises faces coordination complexity that the recall policy may not have anticipated. The named insured, the policy continuity through close, the coordination between selling entity and acquiring entity, and the responsibility for executing the recall response all become questions during the transaction.

The gap forms when the policy’s named insured does not reflect the post-close entity, when change-of-control provisions disrupt continuity, or when the recall response is operationally hampered by the transaction’s organizational uncertainty.

Why it forms. M&A and recall are events that each happen rarely; the intersection of the two is rare enough that policy language typically does not address it explicitly. Standard change-of-control provisions in the policy may trigger underwriter reconsideration just when continuity is most needed.

How to close it. During M&A diligence and pre-close planning, the recall policy should be evaluated against the transaction structure. Tail coverage on the selling entity’s policies, named-insured updates at close, and coordination between buyer’s and seller’s recall programs should be addressed explicitly. The M&A purchase agreement should also address responsibility for any in-progress or imminent recalls and the allocation of related costs.

How Manufacturers Should Approach the Gap Analysis

A structured gap analysis on an existing recall program produces actionable findings.

Read the policy form against the manufacturer’s actual exposure profile. Not against a generic medical device profile. The product portfolio, the distribution geography, the supplier dependencies, the international footprint, and the M&A pipeline all shape what the gap analysis should test.

Sub-limit by sub-limit review. BI, brand rehabilitation, notification, third-party recall, regulatory defense. Each sub-limit should be evaluated for adequacy, not just acknowledged for existence.

Trigger language review. What events activate the policy. Are market withdrawals included. Is the international vigilance event a covered trigger. Is software-driven correction within the recall definition.

Coordination review with adjacent policies. Products liability, property BI, cyber, and clinical trial liability all have potential coverage interactions with recall. The coordination should be intentional rather than left to claim handling.

Document the analysis. A documented gap analysis produces a working document the manufacturer can use at renewal, in M&A diligence, and as part of the broader risk management framework.

A Note on Placement

MedTech Coverage works with medical device manufacturers on recall coverage gap analysis, sub-limit calibration, and the structural decisions that close the most common coverage gaps. Coverage is placed through Tower Street Insurance’s appointments with the specialty life sciences markets that underwrite recall for this segment.

If an existing recall program needs to be evaluated against the manufacturer’s current product portfolio, distribution profile, and supplier dependencies, a structured coverage review produces a working document calibrated to the specific gaps that have formed and the placement changes that close them.